At a glance
A Swiss marketing authorisation transfer is a Swissmedic-approved move of all rights and obligations for named product authorisations to a qualifying future holder. It is separate from buying inventory, changing a company name, signing a distribution agreement or selling shares while the holder remains the same legal entity. The future holder files the transfer and must meet the applicable eligibility conditions. A controlled cutover also needs coordinated dossier, pharmacovigilance, quality, batch, supply, artwork and reimbursement workstreams.
Key takeaways
- Classify the legal event before choosing a Swissmedic route.
- Treat the official filing and the operational handover as connected but separate workstreams.
- Build the date around future-holder readiness, records, stock and safety continuity, not a commercial target alone.
- Do not confuse the current filing lead-time guidance with a guaranteed Swissmedic completion time.
Is the transaction really an authorisation transfer?
A transfer moves the authorisation from one legal entity to another. A purchase of stock, private distribution agreement or share sale that leaves the holder entity unchanged does not by itself transfer the authorisation. A name, legal-form or address change may follow separate guidance, while a merger or legal succession needs scenario-specific evidence.
Map the legal entities before the products. Compare current holder, future holder, commercial-register continuity and intended effective date. Ask a qualified Swiss specialist to confirm the route when the transaction structure is complex; the deal label is not enough.
| Event | Swiss route to investigate | Separate workstream |
|---|---|---|
| Products move from entity A to entity B | Marketing authorisation transfer | Dossier, PV, stock, artwork and supply |
| Same entity changes name, form or address | Name or domicile change guidance | Records, licences and artwork updates |
| Shares are sold but the holder entity remains | Assess whether holder identity changes | Change-of-control and governance clauses |
| Merger or legal succession | Transfer FAQ and commercial-register evidence | Legal continuity, records and licence scope |
| Inventory is purchased | Private stock and GDP arrangement | Does not transfer the authorisation |
What does the current Swissmedic transfer route require?
Swissmedic's current guidance states that the future holder submits the application and must meet the TPA Art. 10 conditions when filing. The package includes the completed form and assignment declaration. The transfer carries the authorisation's rights and obligations while its validity status remains unaffected.
Current guidance asks for filing at least three months before the planned transfer date and requires justification for a shorter lead time. This is a submission-planning rule, not a promise that every case is completed in three months. Recheck forms, guidance version, fees and transitional conditions on the filing date.
Which workstreams must be ready for the cutover?
The future holder needs more than an approval letter. It needs the dossier and eCTD lifecycle, regulatory correspondence, PV cases and commitments, quality and batch records, GMP evidence, product information, artwork, supply agreements, inventory status and the records required to make future decisions.
For reimbursed products, include Specialities List records, FOPH correspondence, price and limitation governance. For each workstream identify old-holder owner, new-holder owner, transfer format, reconciliation, acceptance evidence, cutover action and post-transfer check.
- Regulatory application and effective date
- Establishment licence, RP and market-release readiness
- RPV, cases, signals, PSUR and risk-minimisation handover
- Dossier and eCTD lifecycle migration
- Batch, GMP, samples, deviations and inventory classification
- Product information, artwork and publication
- Supply, customers, complaints, recalls and returns
- Specialities List and FOPH records where relevant
How should stock, batches and packaging be controlled?
After the transfer, the new holder alone may release new batches. It therefore needs sufficient authorisation, batch and GMP records for batches manufactured under the former holder. Stock already placed on the market and packaging transitions are addressed in Swissmedic guidance under defined conditions; they should not be treated as blanket permission.
Separate stock ownership from regulatory status. Classify inventory by manufacture, technical certification, Swiss market release, import, physical location and sale status. Link each population to approved product information and artwork, complaint and recall records, and a responsible owner before the cutover.
How do you protect pharmacovigilance and quality continuity?
PV migration should reconcile cases, signals, periodic reports, risk plans, safety variations, local materials, reporting access, vendor agreements and inspection records. Confirm the future RPV and deputy, their access to global information and the moment at which each responsibility changes.
Quality planning should cover open deviations, complaints, recalls, change controls, supplier qualifications, retained records and samples, temperature events and released stock. Run a joint cutover review and document unresolved items, owners and escalation. This reduces risk but cannot guarantee uninterrupted supply.
What should the readiness gate contain?
Use one controlled readiness gate before confirming the target date. Legal classification, future-holder eligibility, filing package, dossier acceptance, PV and quality migration, market-release capability, stock plan, artwork, supply and reimbursement records should each have evidence and an accountable owner.
Our suggested method is a red-amber-green pack with no green status based only on verbal assurance. This is a project-control method, not a Swissmedic requirement. If a critical dependency remains amber, record the decision, interim control and authority to stop the cutover.
MAH / CH
Swiss authorisation transfer readiness checklist
Use this worksheet to identify owners and evidence before selecting a transfer date.
- Classify the corporate event and confirm the Swissmedic route.
- Verify future-holder eligibility, licence scope, RP and RPV readiness.
- Prepare the current form, assignment evidence and filing plan.
- Inventory the dossier, eCTD lifecycle and regulatory correspondence.
- Reconcile PV cases, signals, commitments, systems and vendor records.
- Classify batches, market-release status, stock, packaging and artwork.
- Map supply, complaints, recalls, returns and customer records.
- Transfer FOPH and Specialities List records where relevant and approve the cutover gate.
Continue exploring
MAH transferQuestions before your next step
Who submits the Swiss authorisation transfer?
Under Swissmedic's current guidance, the future holder submits the application and must meet the applicable holder conditions when filing. The parties also provide the required assignment evidence. Recheck the current form and guidance before submission.
Does Swissmedic complete every transfer within three months?
No. Current guidance asks for submission at least three months before the planned transfer date, with justification for a shorter lead time. That is a planning instruction, not a guaranteed processing time or outcome.
Can existing stock remain on the market after transfer?
Swissmedic guidance contains transitional provisions for stock and packaging under specified conditions. Classify each inventory population and check the current rules, approved information, release status and responsible entity rather than applying a general assumption.
Is a company name change the same as an authorisation transfer?
Not necessarily. Swissmedic has separate guidance for changes to a holder's name or domicile. The correct route depends on legal-entity continuity and the transaction evidence, so classify the event before preparing the workplan.
Can a contract guarantee uninterrupted supply during transfer?
No. Contracts and planning can allocate obligations and reduce risk, but continuity also depends on authority action, future-holder readiness, records, batches, artwork, import, distribution and unexpected quality or safety events. Use explicit readiness gates and contingencies.
Sources and further reading
- Swissmedic guidance: Transfer of marketing authorisation
- Swissmedic questions and answers on authorisation transfer
- Swissmedic guidance: Change of name or domicile
- Swissmedic requirements for the Responsible Person for Pharmacovigilance
- Federal Office of Public Health: Prices of medicines in Switzerland
Independent editorial information for business planning. This is not regulatory or legal advice. Current official guidance prevails; any external specialist introduction is discussed with you first. Please do not send patient data or confidential dossiers.
Free first review
Test the transfer plan before fixing the date
Send a non-confidential summary of your company, product stage and specific question. We review your enquiry and discuss any specialist introduction with you first.
